Dr. Shiv Sabesan is Cytrellis Biosystems’ Chief Technology Officer.

Dr. Shiv Sabesan is Cytrellis Biosystems’ Chief Technology Officer.

In his new role, Dr. Sabesan will lead the company's strategy as it continues to advance its proprietary ellacor Micro-Coring technology and expand indications. The technology was recently featured in Practical Dermatology's sister publication,Modern Aesthetics magazine.

"We are excited to have Shiv Sabesan join Cytrellis' executive leadership team. He brings over 20 years of HealthTech and medical device experience, as well as a proven track record of success," says Jason Richey, President and CEO of Cytrellis Biosystems, in a news release. "I am excited about the innovative perspective he brings and how his passion and expertise aligns with our vision of shaping the future of aesthetic possibilities." 

"I am honored to be joining the Cytrellis team at an opportune time, as ellacor with Micro-Coring Technology continues to transform the aesthetic industry," adds Dr. Sabesan. "As CTO, I look forward to working with this talented team to drive our novel, disruptive technology forward and build a multi-faceted digital ecosystem to optimize ellacor patient outcomes."

Prior to Cytrellis, Dr. Sabesan served as a Principal at Mu!ai, a technology and strategic consulting company focused on providing design development and strategic services in the area of HealthTech, SaaS, AI and medical devices.  In addition to Mu!ai, he has held global roles in research and development and product management at multiple health technology companies.  Dr. Sabesan holds his PhD in electrical engineering from Arizona State University and has  launched more than 10 U.S. Food and Drug Administration/CE regulated medical devices and software, along with market specific healthcare products for the APAC and Latin American regions.